- United States
- /
- Life Sciences
- /
- NasdaqGS:FTRE
Fortrea Holdings First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Fortrea Holdings (NASDAQ:FTRE) First Quarter 2025 Results
Key Financial Results
- Revenue: US$651.3m (down 1.6% from 1Q 2024).
- Net loss: US$562.9m (loss widened by US$483.1m from 1Q 2024).
- US$6.25 loss per share (further deteriorated from US$0.90 loss in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Fortrea Holdings Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 7.1%. Earnings per share (EPS) missed analyst estimates significantly.
Looking ahead, revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US.
Performance of the American Life Sciences industry.
The company's shares are down 9.3% from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Fortrea Holdings, and understanding these should be part of your investment process.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:FTRE
Fortrea Holdings
A contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.
Undervalued with imperfect balance sheet.
Similar Companies
Market Insights
Weekly Picks

An Undervalued 3.3Moz Gold Project in Canada
SoFi Technologies: The Apex Aggregator and the Infrastructure of the Modern Financial System
CSL: The Dip Is the Opportunity
DHT Holdings, inc: Strait of Hormuz Risk Amidst US-Israel vs Iran Tensions Spikes VLCC Rates.
Recently Updated Narratives
Paladin Energy: Betting on the Nuclear Renaissance
Basic-Fit: Why the Market Is Mispricing Europe’s Largest Low-Cost Gym Operator

DroneShield's Growth Will Drive Revenue Up by 25.39% Amidst New Success
Popular Narratives
Nu holdings will continue to disrupt the South American banking market

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks
